Alert date August 10, 2021

CLICK HERE TO OPEN RELATED DOCUMENT

Covid 19 Related Resource

Aug 9 (Reuters)

The mRNA vaccine from Pfizer and BioNTech may be less effective than Moderna’s against the Delta variant of the coronavirus, according to two reports posted on medRxiv on Sunday ahead of peer review.

In a study of more than 50,000 patients in the Mayo Clinic Health System https://bit.ly/37Btmhf, researchers found the effectiveness of Moderna’s vaccine against infection had dropped to 76% in July – when the Delta variant was predominant – from 86% in early 2021.

Over the same period, the effectiveness of the Pfizer/BioNTech vaccine had fallen to 42% from 76%, researchers said.

While both vaccines remain effective at preventing COVID hospitalization, a Moderna booster shot may be necessary soon for anyone who got the Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company nference, who led the Mayo study.

BREAKTHROUGH COVID-19 MORE LIKELY MONTHS AFTER VACCINATION

People who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago, new data suggest. Researchers studied nearly 34,000 fully vaccinated adults in Israel https://bit.ly/3Cucp6O who were tested to see if they had a breakthrough case of COVID-19. Overall, 1.8% tested positive. At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier, the research team reported Thursday on medRxiv ahead of peer review. Among patients older than 60, the odds of a positive test were almost three times higher when at least 146 days had passed since the second dose. Most of the new infections were observed recently, said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel. “Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,” he added. “We are planning to continue our research.”

(Reporting by Nancy Lapid; Editing by Tiffany Wu)